Dendreon shares soar on Provenge survival data
Shares of Dendreon shot up this morning after it released new data showing that patients taking the cosely watched prostate cancer therapy Provenge were less likely to die than patients taking a placebo. But Forbes' Matthew Herper notes that the data may not prove that the drug is effective--even if it does save lives. Release | Report
Be the first to comment
More stories about Dendreon
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


